vs
Side-by-side financial comparison of PLUS THERAPEUTICS, INC. (PSTV) and Meiwu Technology Co Ltd (WNW). Click either name above to swap in a different company.
Meiwu Technology Co Ltd is the larger business by last-quarter revenue ($2.5M vs $1.4M, roughly 1.8× PLUS THERAPEUTICS, INC.). Meiwu Technology Co Ltd runs the higher net margin — -54.9% vs -417.9%, a 363.0% gap on every dollar of revenue. On growth, Meiwu Technology Co Ltd posted the faster year-over-year revenue change (2775.9% vs -3.2%).
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
PSTV vs WNW — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $2.5M |
| Net Profit | $-5.7M | $-1.4M |
| Gross Margin | — | 12.8% |
| Operating Margin | -420.0% | -55.5% |
| Net Margin | -417.9% | -54.9% |
| Revenue YoY | -3.2% | 2775.9% |
| Net Profit YoY | -46.4% | -293.8% |
| EPS (diluted) | $0.95 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4M | — | ||
| Q3 25 | $1.4M | — | ||
| Q2 25 | $1.4M | $2.5M | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | $-5.7M | — | ||
| Q3 25 | $-4.4M | — | ||
| Q2 25 | $5.2M | $-1.4M | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $-3.9M | — | ||
| Q3 24 | $-2.9M | — | ||
| Q2 24 | $-2.9M | — | ||
| Q1 24 | $-3.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 12.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -420.0% | — | ||
| Q3 25 | -320.8% | — | ||
| Q2 25 | -110.6% | -55.5% | ||
| Q1 25 | -333.9% | — | ||
| Q4 24 | -276.2% | — | ||
| Q3 24 | -260.9% | — | ||
| Q2 24 | -289.1% | — | ||
| Q1 24 | -196.7% | — |
| Q4 25 | -417.9% | — | ||
| Q3 25 | -316.6% | — | ||
| Q2 25 | 370.6% | -54.9% | ||
| Q1 25 | -1643.2% | — | ||
| Q4 24 | -276.4% | — | ||
| Q3 24 | -197.4% | — | ||
| Q2 24 | -229.9% | — | ||
| Q1 24 | -194.5% | — |
| Q4 25 | $0.95 | — | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.01 | $-0.03 | ||
| Q1 25 | $-1.19 | — | ||
| Q4 24 | $-0.51 | — | ||
| Q3 24 | $-0.37 | — | ||
| Q2 24 | $-0.71 | — | ||
| Q1 24 | $-0.75 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.6M | $33.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.0M | $58.4M |
| Total Assets | $16.3M | $60.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.6M | — | ||
| Q3 25 | $16.6M | — | ||
| Q2 25 | $6.9M | $33.3M | ||
| Q1 25 | $9.9M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.8M | — | ||
| Q2 24 | $8.4M | — | ||
| Q1 24 | $3.2M | — |
| Q4 25 | $4.0M | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $3.0M | $58.4M | ||
| Q1 25 | $-23.6M | — | ||
| Q4 24 | $-8.9M | — | ||
| Q3 24 | $-5.2M | — | ||
| Q2 24 | $-7.6M | — | ||
| Q1 24 | $-4.8M | — |
| Q4 25 | $16.3M | — | ||
| Q3 25 | $18.7M | — | ||
| Q2 25 | $10.3M | $60.1M | ||
| Q1 25 | $12.1M | — | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $7.0M | — | ||
| Q2 24 | $11.2M | — | ||
| Q1 24 | $5.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $6.7M |
| Free Cash FlowOCF − Capex | $-6.3M | — |
| FCF MarginFCF / Revenue | -459.9% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-20.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | — | ||
| Q3 25 | $-2.5M | — | ||
| Q2 25 | $-5.8M | $6.7M | ||
| Q1 25 | $-6.2M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-1.1M | — | ||
| Q1 24 | $-4.5M | — |
| Q4 25 | $-6.3M | — | ||
| Q3 25 | $-2.6M | — | ||
| Q2 25 | $-5.8M | — | ||
| Q1 25 | $-6.2M | — | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | -459.9% | — | ||
| Q3 25 | -184.3% | — | ||
| Q2 25 | -417.6% | — | ||
| Q1 25 | -583.1% | — | ||
| Q4 24 | -86.5% | — | ||
| Q3 24 | -253.7% | — | ||
| Q2 24 | -96.2% | — | ||
| Q1 24 | -271.5% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 6.3% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.13× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
